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Abstract 
Purpose: To investigate the antibacterial activity of baicalein used alone, or in combination with 
ceftazidime, against Streptococcus pyogenes. 
Methods: Minimum inhibitory concentration (MIC), checkerboard assay parameters, and viability curves 
were determined for S. pyogenes DMST 30653, 30654, and 30655. Cytoplasmic membrane (CM) 
permeability technique, enzyme assays, transmission electron microscopy and Fourier transform-
infrared microspectroscopy were used to investigate the changes in the bacterial biomolecules. 
Results: The MIC of ceftazidime and baicalein against all the S. pyogenes strains were 0.50 and > 
256.0 µg/ml, respectively. A synergistic effect against these strains was exhibited by the 
ceftazidime/baicalein combination (fractional inhibitory concentration index, < 0.37). The results for the 
viable counts indicate that this synergistic activity was present. Baicalein exerted inhibitory activity 
against β-lactamase. Compared with the controls, combining baicalein with ceftazidime caused 
peptidoglycan and morphological damage, significantly increased CM permeability and protein 
concentrations, and decreased cellular fatty acid and nucleic acid concentrations.   
Conclusion: Baicalein is a potential synergistic adjunct to ceftazidime for the treatment of S. pyogenes 
infections. 
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Streptococcus pyogenes (S. pyogenes), group A 
streptococcus, is the most common cause of 
bacterial pharyngitis, scarlet fever, and impetigo. 
S. pyogenes is also the group mostly associated 
with streptococcal toxic shock syndrome [1]. In 
the past two decades, increases in severe S. 
pyogenes diseases have been reported 
worldwide [2]. Recommended therapies for S. 
pyogenes infections include the use of penicillins 
and cephalosporin. However, the failure of 
penicillin to eradicate streptococci from the throat 
occurs in up to 35 % of patients with pharyngeal-
tonsillitis [3]. 
  
Previous research results indicate that 1.9% of S. 
pyogenes infections exhibit intermediate 
resistance to ampicillin [4]. Khan and co-worker 
found S. pyogenes resistant to cloxacillin, 
oxacillin, and cefoperazone [5]. The only two 
described S. pyogenes strains are β-lactamase 
producers, and bla-TEM has been detected and 
amplified on genomic DNA of 28 β-lactam 
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resistant isolates from 42 S. pyogenes infections 
from Mansoura university hospitals [6]. 
  
Co-existing oropharyngeal beta-lactamase-
producing bacteria (BLPB) may not only have 
survived penicillin therapy, but also could have 
protected other penicillin-susceptible bacteria 
from penicillin. Increased failure rates for 
penicillin used for treatment of otitis, sinusitis, 
and pharyngeal-tonsillitis infections associated 
with these bacteria have been reported [7]. 
Effective antibiotics available for the treatment of 
S. pyogenes and coexisting BLPB infections are 
frequently associated with β-lactam failure and 
unwanted side effects. Discovery of new 
combination agents to treat these bacteria, 
overcome β-lactam failures during S. pyogenes 
treatment and the resurgence of BLPB infections, 
and reduce adverse drug effects, is urgently 
needed. Many flavonoids isolated from plants 
have shown synergistic antibacterial activity [8]. 
  
The aim of the present study was to investigate 
the antibacterial and synergistic activities of 
baicalein, alone and in combination with 
ceftazidime, against S. pyogenes. The basic 




Materials and bacterial strains 
 
Streptococcus pyogenes DMST 30653, 30654, 
and 30655 were obtained from the Department of 
Medical Sciences, Ministry of Public Health, 
Thailand. Staphylococcus aureus ATCC 29213 
(S. aureus) was purchased from the American 
Type Culture Collection (ATCC; Virginia, USA), 
and was used as a positive control. Baicalein 
(purity 98 %) was purchased from the Indofine 
Chemical Company (New Jersey, USA). 
Ceftazidime, amoxicillin, penicillin, β-lactamase 
type IV, dimethylsulfoxide, glutaraldehyde (grade 
I, 25 %; for electron microscopy (EM)), osmium 
tetroxide (4 %; for EM), a Spurr Low-Viscosity 
Embedding Kit, and nisin (from Lactococcus 
lactis, 2.5 %, balanced sodium chloride and 
denatured milk solids) were obtained from Sigma 
(Sigma-Aldrich, Dorset, UK). Mueller-Hinton agar 
(MHA), Mueller–Hinton broth with sheep blood (5 
% v/v) agar (MHBSB), cation-adjusted Mueller-
Hinton broth (CAMBH), and cation-adjusted 
Mueller-Hinton broth with lysed horse blood (2.5 
% v/v) (CAMHBHB) were obtained from Oxoid 
(Basingstoke, UK). 
 
Bacterial suspension standard curve 
 
The bacterial suspensions standard curve 
method was used to determine known viable 
counts, following the method of Richards and 
Xing with few modifications [9]. Viable counts for 
each absorbance reading were determined in 
triplicate using an agar plate counting method 
[8,10].  
 
Minimum inhibitory concentration (MIC) 
 
MIC determinations of ceftazidime, amoxicillin, 
penicillin, nisin, and baicalein against the S. 
pyogenes and S. aureus strains were performed 
using previously reported methods [8,10,11]. 
Briefly, in addition to an antibacterial or baicalein, 
an inoculum of 5 x 106 cfu/ml bacterial 
suspension was added to each tube containing 
CAMHBHB (for S. pyogenes) or CAMBH (for S. 
aureus), to result in approximately 5 x 105 cfu/ml 
per tube. The MIC determination was 
accomplished by observing turbidity after 20 h of 




Checkerboard assays to determine the 
synergistic activity of baicalein in combination 
with ceftazidime against all tested S. pyogenes 
strains were performed following Eumkeb et al 
[8]. The interaction between the two agents was 
calculated using the fractional inhibitory 
concentration index (FICI) [12]. The FICI 
categories were: synergistic (FICI, ≤ 0.5), 
partially synergistic (FICI, > 0.5 and < 1.0), 
additive (FICI, 1.0), indifferent (FICI, > 1 and ≤ 
4.0), and antagonistic (FICI, > 4.0). 
Staphylococcus aureus was used as positive 
control.  
 
Determination of viability curves 
 
Killing curve determination was performed to 
confirm the synergistic activity of the combination 
following the methods of Richards and Xing, 
Eumkeb et al, and the Clinical and Laboratory 
Standards Institute, with slight modifications 
[8,9,11]. After the FIC index was obtained, the 
MIC of each compound that was associated with 
the synergism FIC index for the combination was 
chosen for investigation. The half-MICs of 
ceftazidime and baicalein separately, and that of 
their combination, yielded the synergistic FIC 
index against S. pyogenes.   
 
Cytoplasmic membrane (CM) permeability 
test 
 
The CM permeabilization experiment was 
performed, with some modifications, to confirm 
results as previously described by Shen et al and 
Zhou et al [13,14]. Shortly after the FIC index 
was determined from the checkerboard assay, 
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the half-MIC values for ceftazidime and baicalein 
alone, and the 3/4 MIC values for these 
combinations that resulted in synergistic FIC 
indices, were selected against S. pyogenes to 
measure CM permeability. This method was 
performed by measuring the release of UV-
absorbing material (Varian's Cary 100 UV-Vis 





The β-lactamase type IV of Enterobacter cloacae 
inhibition activity was previously described by 
Reading and Farmer [16]. The analyses of the 
remaining substrates were performed using 
reverse-phase HPLC with an 
acetronitrile/ammonium acetate mobile phase 
[16]. 
 
Transmission electron microscopy (TEM) 
 
Cellular damage of the bacteria was examined 
using TEM. Briefly, after the FIC index was 
obtained from checkerboard assay, the half-MIC 
values for ceftazidime and baicalein alone, and 
the 3/4 MICs for the combinations that gave 
synergistic FIC indices, were chosen against S. 
pyogenes to investigate the morphological 
appearance. Subcultures were prepared for 
examination using TEM, based the method of 
Eumkeb et al [8].  
 
Fourier Transform-Infrared (FT-IR) 
microspectroscopy  
 
FT-IR measurement was performed following the 
methods of Eboigbodin and Biggs, and Toubas 
et al [17,18]. Briefly, after the FIC index was 
illustrated from the checkerboard assay, the half-
MIC for ceftazidime alone and the 0.75 MIC for 
the combination that gave a synergistic FIC index 
against S. pyogenes were used in FT-IR studies 
[17-19]. The cells were incubated at 37 °C in a 
shaking water bath for 4 h. The cell pellets were 
centrifuged at 3000 x g for 10 min and washed 
twice with saline. The cells were then washed 
twice with Milli-Q water. A small portion of pellet 
was then deposited into a Mirr IR low e-
microscope slide (Kevey slide) to use as a 
substrate for FT-IR microscope analysis. The 
cells were then desiccated under a vacuum for 
approximately 20 min and stored in desiccators 
to form acceptable films before analysis. To 
achieve high S/N ratios, 64 scans were coded for 
each measurement in the wavenumber between 
4000 and 400 cm-1 resolution of 6 cm-1. Spectra 
were recorded in reflection mode on a Bruker IR 
spectrometer (Tensor 27, Massachusetts, USA) 
coupled to an IR microscope (Hyperion 2000, 
Bruker) with 36x magnification. The data for the 
effects of variation of the composition and 
distribution of the biochemical components in the 
bacterial cells during cell culture were analyzed 
using principal components analysis (PCA). All 
data analysis was performed in the 3000 – 2800 
cm-1 and 1800 – 850 cm-1 spectral ranges, which 




All experiments were carried out in triplicate; 
results were expressed as mean ± standard error 
of the mean (SEM). Significant differences in CM 
permeability, the enzyme assay data between 
each treated group at the same interval times, 
and the peak area in each group of FT-IR range 
were analyzed using one-way ANOVA. A 0-value 
< 0.01, based on Scheffe's post-hoc test, was 





MIC and FIC 
 
The MIC results for ceftazidime, nisin, and 
baicalein against S. pyogenes tested strains are 
presented in Table 1. The results revealed that 
the MICs for ceftazidime, nisin, and baicalein 
against all S. pyogenes strains were 0.50, 1.0, 
and > 256 µg/ml, respectively. These results 
indicated that these strains were sensitive to 
ceftazidime [11]. Staphylococcus aureus ATCC 
29213, a positive control, was susceptible to 
amoxicillin and penicillin [11]. Baicalein exhibited 
little inhibitory effect against this strain. The FIC 
indices for ceftazidime plus baicalein against all 
S. pyogenes strains were < 0.37. These results 
indicated that these combinations showed 




The results for the separate and combined 
effects of ceftazidime and baicalein on viable 
counts of S. pyogenes 30653 are presented in 
Figure 1. The viable counts for the cells treated 
with ceftazidime were slightly lower than that of 
baicalein (between 2 and 24 h). The combination 
of ceftazidime and baicalein dramatically 
decreased the cell count to 6 x 103 cfu/ml after 6 
h and up to 24 h. 
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Table 1: Minimum inhibitory concentrations (MICs), fractional inhibitory concentrations (FICs), and FIC indices for 
ceftazidime, amoxicillin, penicillin, nisin, and baicalein, alone or in combination, against S. pyogenes strains 
   
Strain   MIC (g/ml)  FIC (g/ml) FIC index 
 cef amo pen nis bai cef + bai cef + bai 
S. pyogenes DMST 
30653 
0.50s N/D N/D 1.0 >256.0 0.12 +32.0 <0.37 
S. pyogenes DMST 
30654 
0.50s N/D N/D 1.0 >256.0 0.12 +32.0 <0.37 
S. pyogenes DMST 
30655 
0.50s N/D N/D 1.0 >256.0 0.12 +32.0 <0.37 
S. aureus ATCC 
29213* 
N/D <0.2s <0.1s N/D N/D N/D N/D 
*S. aureus ATCC 29213, amoxicillin and penicillin were used as positive control; cef = ceftazidime, amo = 
amoxicillin, pen = penicillin, nis = nisin, bai = baicalein; s = susceptible; N/D = No data; n = 3 
 
These results were confirmed by the 
checkerboard assay results, which indicated that 
the combination produced a decrease of ≥ 2 
log10 cfu/ml, compared with ceftazidime 




Figure 1: The effects of ceftazidime and baicalein, 
alone and in combination, on the viable counts of S. 
pyogenes DMST 30653; () = control (drug-free); () 
= baicalein, 128 µg/ml; () = ceftazidime, 0.25 µg/ml; 
() = ceftazidime, 0.12 µg/ml, plus baicalein, 32 
µg/ml; n = 4; error bars indicate the standard error of 
the mean (SEM) 
 
CM permeability  
 
The CM permeability was measured by 
examining the release of UV-absorbing materials 
(Figure 2). After treatment, S. pyogenes 30653 
cells with nisin, ceftazidime, and the ceftazidime 
plus baicalein combination could induce the 
release of 260 nm absorbing materials at 
significantly higher levels compared with the 
control or baicalein alone (p < 0.01). The CM 
permeability strength was nisin > ceftazidime 
plus baicalein > ceftazidime > baicalein > control 
(p < 0.01). These results suggested that the 
synergistic activity of ceftazidime plus baicalein 
mostly resulted in increased cytoplasmic 
membrane permeability of DNA, RNA, and 




Figure 2: Effect of 260 nm absorbing material (DNA, 
RNA, and metabolites) in the S. pyogenes DMST 
30653 supernatants treated with baicalein and 
ceftazidime either alone or in combination. () = 
control (drug-free); () = baicalein, 128 µg/ml; () = 
ceftazidime, 0.25 µg/ml; () = ceftazidime, 0.09 µg/ml, 
plus baicalein. 24 μg/ml; () = nisin, 0.50 μg/ml. Nisin 
(0.50 µg/ml) was used as a positive control and 
untreated cells were used as a negative control; n = 3; 
means sharing the same superscript are not 
significantly different (Scheffe's test, p < 0.01) 
 
Enzyme assay  
 
The enzyme assay results for the baicalein 
treatment revealed that the levels of 
benzylpenicillin were significantly higher 
compared with the controls (p < 0.01). The levels 
of benzylpenicillin depended on the baicalein 
concentration in a decreasing, dose-dependent 
manner (p < 0.01). 
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The transmission electron micrographs of cells 
from the log phase of growth of S. pyogenes 
30653 in the presence of ceftazidime, baicalein, 
and ceftazidime + baicalein are presented in 
Figure 3. The peptidoglycan and cytoplasmic 
membranes could be distinguished, and the cells 
had the normal appearance of the control group 
(Figure 3a). The micrographs of the S. pyogenes 
30653 cells treated with ceftazidime or baicalein 
alone revealed that cell division may have been 
interrupted, which resulted in cell shape 
distortions (Figure 3b and 3c). The results for the 
combination-treated cells also indicated that cell 
division in many of these cells may have been 
interrupted, leading to twisted and irregular cell 
shapes, and peptidoglycan and cytoplasmic 
membrane damage (Figure 3d). The average 
areas of these cells were significantly larger 
compared with the control cells (p < 0.01). 
 
FT-IR spectra  
 
The 3-dimensional PCA clustering results from 
the FT-IR spectral data for S. pyogenes 30653 
after treatment with ceftazidime alone and in 
combination with baicalein are presented in 
Figure 4a. The biomolecule fingerprint clusters 
for the control and the ceftazidime alone or in 
combination with baicalein groups were clearly 
differentiated [23,27]. 
 
The S. pyogenes 30653 strain was grown in 
CAMHBHB medium in the presence of 
ceftazidime or the ceftazidime plus baicalein 
combination, and examined using FT-IR 
microspectroscopy. The results for the loading 
plots are presented in Figure 4b. The signal 
intensities and peak areas of these treated cells 
at ~1655 and ~1637 cm-1 were ceftazidime plus 
baicalein > ceftazidime > control, which 
corresponded to an absorption peak for the 
secondary structure of protein amide I (α-helix 
and β-sheet). The peak intensity pattern for the 
areas at ~1085 cm-1 was  ceftazidime > control > 
ceftazidime plus baicalein, which correlated with 
an absorption peak for a nucleic acid (DNA and 






Figure 3: Ultrathin sections of log phase S. pyogenes DMST 30653 grown in cation-adjusted Mueller-Hinton 
broth with lysed horse blood (2.5 %v/v) containing: a, control (drug-free); b, ceftazidime, 0.25 μg/ml; c, baicalein, 
128 μg/ml; d, ceftazidime, 0.09 μg/ml, plus baicalein, 24 μg/ml. (a, 195,000x, bar 500 nm; b, 7,000x, bar 1 µm; c, 
19,500x, bar 500 nm; d, 7,000x, bar 1 µm; Inset: a, 26,000x, bar, 200 nm; b, 19,500x, bar, 500 nm; c, 19,500x, 
bar, 500 nm; d, 19,500x, bar, 500 nm) 
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The second loading of the treated and control 
groups indicated that the obvious regions at 
3000–2800 cm-1 (~2963, ~2921, ~2875, ~2852 
cm-1) could be attributed to the stretching modes 
of CH2 and CH3 in the fatty acids located on the 
various membrane amphiphiles and ester bands, 
respectively (Figure 4d) [25,26]. The treated cells 
exhibited a peak area and intensity at ~2921 and 
~2852 cm-1, respectively, of ceftazidime > control 




The presence of BLPB after treatment indicated 
that the bacteria may not only have survived 
penicillin therapy, but also could have protected 
other penicillin-susceptible bacteria from the drug 
and led to the failure of penicillin to eradicate this 
strain from the patients with pharyngeal-tonsillitis 
[28]. A novel antibacterial combination that can 
conquer β-lactam failures for treatment of S. 
pyogenes and the coexistence of the BLPB 
infections is urgently required. The MIC results 
revealed that all of the S. pyogenes strains were 
still sensitive to ceftazidime alone. The standard 
values for the sensitivities of cefotaxime (also a 
third-generation cephalosporin) against these 
strains are ≤ 0.50 µg/ml [11].  
 
The checkerboard assay revealed that there 




Figure 4: Principal components analysis (PCA) results (a); the loading plot for the first (PC1) and the second 
(PC2) principal components obtained from the PCA of S. pyogenes DMST 30653 (b); the representative second 
derivative transformation spectra (1800–1000 cm-1) (c); and the representative second derivative transformation 
spectra (3000–2800 cm-1) (d). Symbols represent the FT-IR spectra of, a, c, d, () = control (drug-free), () = 
ceftazidime, 0.25 µg/ml () = ceftazidime, 0.09 µg/ml, plus baicalein, 24 μg/ml; b, solid line = PC1, dotted line = 
PC2 
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strains when ceftazidime was combined with 
baicalein (FIC index < 0.37) [12]. The killing 
curve result (≥ 2 log10 cfu/ml reduction) also 
confirmed the synergistic effect of ceftazidime 
plus baicalein, compared with ceftazidime alone 
[20]. 
 
The CM permeability results indicated that the 
ceftazidime plus baicalein combination clearly 
increased CM permeability of S. pyogenes. To 
our knowledge, this study is the first to reveal this 
effect. An increase in CM permeability may be 
one of the synergistic actions of this combination 
against S. pyogenes. These findings provide 
evidence that the phospholipid bilayer in the 
cytoplasmic membrane might have been 
destroyed, with a resultant leak in the plasma 
membrane [14].  
 
The enzyme assay revealed that baicalein had 
an inhibitory activity against β-lactamase. 
Whether S. pyogenes produces beta-lactamase 
or not, a previous study found that the beta-
lactamase produced by other bacteria in the 
pharynx can inactivate penicillin, which can result 
in increased treatment failures or infection 
relapses [29]. These findings provide evidence 
that baicalein in combination with beta-lactam 
antibiotics may useful for the inhibition of the 
coexistence of the BLPB and S. pyogenes in 
oropharyngeal infections. 
 
The TEM results for the changes in the S. 
pyogenes cells after exposure to ceftazidime plus 
baicalein indicated that the division of many of 
the bacterial cells may have been interrupted. 
This effect likely led to the twisted and irregular 
cell shapes, the peptidoglycan and cytoplasmic 
membrane damage, and the significant increase 
in average cell area (p < 0.01). These results can 
be explained by assuming that baicalein may 
interact synergistically with ceftazidime to inhibit 
peptidoglycan synthesis. This synergistic effect 
can result in marked morphological damage and 
delayed cell division.  
  
Our FT-IR results indicated that compared to the 
controls, S. pyogenes cells treated with baicalein 
in combination with ceftazidime had increased  
the α-helical and β-pleated sheet structures of 
amide I, but had decreased nucleic acids and 
fatty acid content  in the bacterial cells [24]. 
These results suggested that this combination 
may damage the composition of the fatty acid 
chains on the phospholipid bilayer of the plasma 
membrane and interrupt peptidoglycan synthesis. 
The amide I transformation results in CM 
damage and increased permeability, DNA and 
RNA leakage, and amide I protein accumulation 
within the cells. 
CONCLUSION 
 
This study provided evidence that baicalein and 
ceftazidime have a synergistic effect against S. 
pyogenes. To our knowledge, this is the first 
report on the mechanisms of synergistic action of 
baicalein and ceftazidime against this strain 
using FT-IR. The modes of actions of this 
combination included inhibition of peptidoglycan 
synthesis, increased CM permeability and 
enhanced amino acid accumulation, but reduced 
fatty acid and nucleic acid quantities, in the 
bacterial cells. Because baicalein has limited 
toxicity, it can potentially be used as an adjunct 
to ceftazidime for the treatment of coexisting 
BLPB and S. pyogenes infections. Future studies 
are required to confirm that this synergism 
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